**Name of Journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 42016**

**Manuscript Type:** **ORIGINAL ARTICLE**

***Retrospective Study***

**Relationship between the response to lusutrombopag and splenic volume**

Uojima H *et al.* Lusutrombopag treatment and splenic volume

Haruki Uojima, Yoshitaka Arase, Norio Itokawa, Masanori Atsukawa, Takashi Satoh, Koji Miyazaki, Hisashi Hidaka, Ji Hyun Sung, Makoto Kako, Kota Tsuruya, Tatehiro Kagawa, Katsuhiko Iwakiri, Ryouichi Horie, Wasaburo Koizumi

**Haruki Uojima, Ji Hyun Sung, Makoto Kako,** Department of Gastroenterology, Shonan Kamakura General Hospital, Kamakura 247-8533, Japan

**Haruki Uojima, Hisashi Hidaka, Wasaburo Koizumi,** Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Kanagawa 252-0375, Japan

**Yoshitaka Arase, Kota Tsuruya, Tatehiro Kagawa,** Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa 259-1193, Japan

**Norio Itokawa,** Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital, Chiba 270-1694, Japan

**Masanori Atsukawa, Katsuhiko Iwakiri,** Department of Internal Medicine, Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo 113-8603, Japan

**Takashi Satoh, Ryouichi Horie,** Division of Hematology, Department of Medical Laboratory Sciences, Kitasato University School of Allied Health Sciences, Kanagawa 252-0375, Japan

**Takashi Satoh, Ryouichi Horie,** Division of Molecular Hematology, Kitasato University Graduate School of Medical Sciences, Kanagawa 252-0375, Japan

**Koji Miyazaki,** Department of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Kanagawa 252-0375, Japan

**ORCID number:** Haruki Uojima (0000-0003-1719-1352); Yoshitaka Arase (0000-0001-8498-3128); Norio Itokawa (0000-0002-3321-4532); Masanori Atsukawa (0000-0003-3374-7111); Takashi Satoh (0000-0002-0728-3125); Koji Miyazaki (0000-0002-0883-2851); Hisashi Hidaka (0000-0002-4151-5663); Ji Hyun Sung (0000-0002-3614-1740); Makoto Kako (0000-0002-6447-8471); Kota Tsuruya (0000-0002-9884-8039); Tatehiro Kagawa (0000-0002-3442-1423); Katsuhiko Iwakiri (0000-0002-5558-6104); Ryouichi Horie (0000-0002-2431-2290); Wasaburo Koizumi (0000-0001-9972-1083).

**Author contributions:** Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung J, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W contributed equally to this work; Uojima H, Arase Y and Itokawa N collected and analyzed the data; Uojima H drafted the manuscript; Hidaka H designed and supervised the study; Atsukawa M, Satoh T, Miyazaki K, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R and Koizumi W offered technical or material support; all authors discussed the results and commented on the manuscript.

**Institutional review board statement:** The study was reviewed and approved by the Tokushukai Group Ethical Committee’s institutional review board.

**Informed consent statement:** This study is a retrospective observational study. Informed consent was obtained from all individual participants included in the study by the opt-out method of our hospital website.

**Conflict-of-interest statement:** We declare no conflicts of interest.

**Data sharing statement:** The technical appendix, statistical code, and dataset are available from the corresponding author (email: kiruha@kitasato-u.ac.jp).

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** **Haruki Uojima, MD, PhD, Doctor,** Department of Gastroenterology, Shonankamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa 247-8533, Japan. kiruha@kitasato-u.ac.jp

**Telephone:** +81-467-461717

**Fax:** +81-467-450190

**Received:** September 12, 2018

**Peer-review started:** September 12, 2018

**First decision:** October 14, 2018

**Revised:** October 20, 2018

**Accepted:** November 9, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To assess the correlation between the efficacy of lusutrombopag and clinical characteristics in patients with chronic liver disease.

***METHODS***

In this retrospective, multicenter study, which conducted at four locations in Japan, 50 thrombocytopenic patients with chronic liver disease enrolled. All patients received oral lusutrombopag (3.0 mg/d for 7 d) for chronic liver disease. We assessed the increase in platelet count after the trial drug administration. A treatment response defined as platelet counts of ≥ 5 × 104/μL and an increase of platelet counts of ≥ 2 × 104/μL from baseline after drug administration. We evaluated the response to lusutrombopag compared to baseline clinical characteristics in patients with chronic liver disease.

***RESULTS***

The number of responders and non-responders were 40 (80.0%) and 10 (20.0%), respectively. Patients divided into the responder and non-responder groups, and we added factors that may correspond to successful treatment with lusutrombopag. Splenic volume and body weight were lower in the responder group than those in the non-responder group. White blood cell counts and hemoglobin levels were higher in responders compared with those in non-responders. Using a logistic regression model to assess the relationship between response to lusutrombopag and clinical characteristics, multivariate analysis confirmed that splenic volume was an independent factor that predicted the response of platelet counts (*P* = 0.025, odds ratio: 11.2; 95% confidence interval, 1.354-103.0). Splenic volume negatively correlated to changes in platelet count (*r* = -0.524, *P* = 0.001).

***CONCLUSION***

Splenic volume influences change in platelet counts after administration of lusutrombopag in patients with chronic liver disease.

**Key words:** Lusutrombopag; Portal hypertension; Splenic volume; Thrombocytopenia; Thrombopoietin receptor agonist

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Lusutrombopag is an oral, small-molecule thrombopoietin receptor agonist used for the treatment of thrombocytopenic patients with chronic liver diseases. However, the response to this drug is unpredictable. The study aimed to assess the correlation between the clinical characteristics of patients with chronic liver disease and the efficacy of lusutrombopag treatment. Splenic volume influences change in platelet counts after administration of lusutrombopag in patients with chronic liver disease. Splenic volume increase negatively related to changes in the platelet count.

Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung Ji Hyun, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W. Relationship between the response to lusutrombopag and splenic volume. *World J Gastroenterol* 2018; In press

**INTRODUCTION**

Thrombocytopenia is a common complication of end-stage liver disease that leads to portal hypertension[1,2]. Severe thrombocytopenia can significantly increase a patient's risk of bleeding, especially during surgery or other invasive procedures[3]. Some cirrhotic patients with severe thrombocytopenia require blood transfusions prior to an invasive surgery[4]. However, platelet transfusion poses some risks, such as bacterial contamination, severe allergic reaction, and alloimmunization to platelets[5]. Therefore, to minimize the administration of transfusion, additional methods for reducing the incidence of bleeding events in thrombocytopenic patients are required.

Lusutrombopag is an oral, small-molecule thrombopoietin (TPO) receptor agonist (TPO-RA) used for the treatment of thrombocytopenic patients with chronic liver diseases. This new drug promotes thrombopoiesis *via* the human TPO receptor on the surface of bone marrow cells[6]. TPO production is dependent on functional liver cells, and TPO in the peripheral blood in advanced-stage liver disease severely reduced. Therefore, patients with inadequate TPO production due to chronic liver disease are the principal targets of treatment with lusutrombopag[7].

However, the response to this drug is unpredictable, assuming that the drug may exerts more dramatic effects in patients with thrombocytopenia associated with severe liver disease prior to invasive surgery. Therefore, the study aimed to assess the correlation between the clinical characteristics of patients with chronic liver disease and the efficacy of lusutrombopag treatment.

**MATERIALS AND METHODS**

***Ethics***

This study approved by the Institutional Review Board Ethics Committee at all four institutes. This study registered in the UMIN Clinical Trials Registry as UMIN 000031354.

***Populations***

This multicenter retrospective study conducted at four locations in Japan. Enrollment commenced February 2015 and ended at the end of March 2018. This study enrolled thrombocytopenic patients, who received oral lusutrombopag (3.0 mg/d for 7 d), and from whom blood samples to analyze changes in platelet counts were collected on day 1, 5, 12 (or the maximum count), and 28, according to the manufacturer’s prescription guidelines. The enrolled thrombocytopenic patients had chronic liver disease, which was composed of either cirrhosis or non-cirrhosis. Cirrhosis in these patients were caused by hepatitis C, hepatitis B, alcoholic or non-alcoholic steatohepatitis, primary biliary cholangitis, and autoimmune hepatitis. Non-cirrhotic patients were composed of patients with idiopathic portal hypertension, the Budd-Chiari syndrome, or an extrahepatic portal venous obstruction. The diagnosis of cirrhotic and non-cirrhotic diseases was based on laboratory results and imaging tests that revealed a hepatic cirrhotic appearance, gastroesophageal varices, ascites, splenomegaly, portal vein obstruction, and/or portal collateral circulation. Liver biopsy not performed for any of the patients with liver cirrhosis because of the high risk of life-threatening complications. Any patients with hematologic disease, past history of thromboembolism, who underwent blood or platelet transfusions in the previous 2 wk, or those who had changes in their doses of conventional drugs were excluded.

***Clinical parameters***

General characteristics, demographic information, procedures, and all laboratory data, except for serological data, obtained during the administration of the trial drug. Laboratory tests are included: Platelet count, hemoglobin, white blood cell count, percent prothrombin time, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein level, albumin, blood urea nitrogen, creatinine, total bilirubin, HbA1c, α-fetoprotein (AFP), and protein induced by vitamin K absence-II (PIVKA-II). Two non-invasive fibrosis markers and an algorithm-based score model were calculated as follows. (1) AST to platelet ratio index (APRI): APRI = [AST (/35 IU/L) / platelets (103/μL)] × 100; (2) Fibrosis 4 (FIB-4) index: FIB-4 = [AST (IU/L) × Age (years)] / [ALT (IU/L) × platelets (103/μL)]; (3) Model for end-stage liver disease (MELD): MELD = 3.78 × loge [serum bilirubin (mg/dL)] + 11.2 × loge [PT-INR] + 9.57 × loge [serum creatinine (mg/dL)] + 6.43. Calculation of splenic volume, portal vein diameter, and splenic vein diameter in patients with chronic liver disease conducted *via* abdominal computed tomography (CT) on a multidetector scanner during a 6-mo period. After image acquisition, the data transferred to an image processing workstation. Five-millimeter slices from enhanced CT images obtained of the entire spleen outlined using a semi-automatic segmentation technique by an experienced radiological technologist. Volume software on the workstation computer calculated the total splenic volume by adding the slice thickness to determine the volume for each section of the spleen[8] (Figure 1).

***Evaluation of treatment response and safety assessments***

We investigated an increase in platelet count after the trial drug administration. We evaluated the response to lusutrombopag compared to baseline clinical characteristics in patients with chronic liver disease. According to a phase 3 trial, a treatment response was defined as a platelet count of ≥ 5 × 104/μL with an increased platelet count of ≥ 2 × 104/μL from baseline after drug administration[6-9].

We also evaluated adverse events at each visit. The data on all adverse events was collected from the start of the administration to up to 90 d after the first dosing. The severity of any adverse events was graded using CTCAE (Common Terminology Criteria for Adverse Events), version 4.0.

***Statistical analysis***

Our estimation of the response rates in thrombocytopenic patients was 83% based on previous studies[9]. With an alpha of 0.05 and power of 80%, 50 patients were required for this trial. Data analyzed using the SPSS v.24.0 software package (IBM Corp., Armonk, NY, United States). All data expressed as mean and standard deviation (SD) values. Continuous variables in the responder and non-responder groups compared using unpaired *t*-test. The paired *t*-test used to compare paired data. Correlations between the changes in platelet count and clinical characteristics were determined using Pearson’s *r* coefficient. Receiver-operating characteristic (ROC) curves constructed to establish sensitivity-specificity relationships. Univariate and multivariate analyses with logistic regression models were used to calculate the odds ratios (OR) and 95% confidence intervals (CI) were used to assess the correlation between response and clinical characteristics. We categorized patients into two groups in each variable using a median value. Variables that achieved statistical significance (*P* < 0.05) or marginal significance (*P* < 0.15) on univariate analysis entered into a multivariate Cox proportion hazard model to identify significant independent factors. All differences with a *P*-value of < 0.05 were considered statistically significant. The statistical methods of this study been reviewed by the Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital, Hokkaido, Japan.

**RESULTS**

***Participating patients***

A total of 59 patients were treated with lusutrombopag from February 2015 through March 2018 in the four study centers. Of these, 6 patients did not meet the above inclusion criteria (3 patients received an insufficient dose of the trial drug during the period of the study, 2 patients had a change in the doses of their conventional drugs, and 1 patient received a platelet transfusion before day 12). When we assessed the remaining 53 patients for eligibility, 3 patients were excluded because of missing data regarding their splenic volume and/or their blood samples. The data of the remaining 50 patients are summarized in Table 1. The mean age was 65.9 ± 10.2 years (range, 48-83 years), 34 patients (68.0%) were male, and 26 patients (52.0%) had liver cancer. The mean body weight was 64.7 kg ± 12.1 kg (range, 46.5-93.0 kg), and the mean height was 1.63 m ± 0.10 m (range, 1.20-1.81 m). Forty-eight patients (96.0%) had liver cirrhosis caused by hepatic viruses (*n* = 21) and non-hepatic viruses (*n* = 27). The mean platelet count was 4.48 ± 1.07 × 104/μL (range, 3-7 × 104/μL), albumin was 3.46 g/dL ± 0.54 g/dL (range, 2.2-4.5 g/dL), serum creatinine was 0.82 mg/dL ± 0.21 mg/dL (range, 0.49-1.61 dL), AST was 47.4 IU/L ± 25.6 IU/L (range, 15-133 IU/L), total bilirubin was 1.41 g/dL ± 0.83 g/dL (range, 0.6-4.9 g/dL), and AFP was 33.4 ng/mL ± 82.7 ng/mL (range, 2-479 ng/mL). According to non-invasive fibrosis markers and an algorithm-based score model, the mean MELD score was 7.26 ± 3.05 (range, 2-16), APRI was 31.3 ± 17.3 (range, 11-80), and the FIB 4 index was 12.4 ± 5.49 (range, 4.51-25.7). The numbers and proportions of invasive procedures in radiofrequency ablation, interventional radiology, and endoscopic therapy were 14 (28%), 10 (20%), and 22 (44%), respectively.

***Clinical effect***

The numbers and proportions of patients in the responder and non-responder groups were 40 (80%) and 10 (20%), respectively. After treatment with oral lusutrombopag for all enrolled patients, a significant increase in the mean platelet count from 4.49 ± 1.03 × 104/μL pre-treatment to 9.13 ± 3.50 × 104/μL post-treatment observed. Change in platelet counts on day 5, 12, and 28 were 1.16, 4.64, and 1.02 (*P* = 0.001, *P* < 0.001, and *P* = 0.003, respectively) (Figure 2). All patients had sufficient platelet counts (platelet count ≥ 5 × 104/μL) except 2 patients (platelet count < 5 × 104/μL) who received blood transfusions prior to an elective invasive procedure. After the invasive procedures, there were no instances of spontaneous bleeding.

***Thrombocytopenic patients received blood transfusions***

In the non-responder group (*n* = 10), 2 patients received platelet transfusion prior to an elective invasive procedure. One patient was a woman with HCV-related liver cirrhosis, and the splenic volume was 890 mL. Her on pre-treatment, post-treatment, and post-platelet transfusion platelet counts were 4.1, 5.5, and 6.5 × 104/μL, respectively. Another patient was a man with HBV-related liver cirrhosis, and the splenic volume was 1720 mL. His platelet counts on pre-treatment, post-treatment, and post-platelet transfusions were 4.0, 4.8, and 5.2 × 104/μL, respectively.

***Clinical characteristics of responder patients***

Splenic volume was significantly lower in responders compared with non-responders (653.0 mL ± 267 mL *vs* 1,092 mL ± 314 mL, *P* < 0.0001) (Table 1). Body weight was lower in the responder group compared to that in the non-responder group (63.0 ± 11.3 kg *vs* 71.6 ± 13.4 kg, *P* = 0.044). White blood cell and hemoglobin counts were higher in the responder group than those in the non-responder group (3330 μL ± 1051/μL *vs* 2480 μL ± 681/μL, *P* = 0.020, and 12.4 g/dL ± 1.84 g/dL *vs* 10.7 g/dL ± 2.82 g/dL, *P* = 0.026, respectively). Furthermore, the responder group had slightly more males than females (*P* = 0.138). No significant differences was found between the two groups with respect to age, body mass index, etiology, the presence of liver cancer, the Child-Pugh score, the MELD score, and the APRI and FIB 4 indices. No significant differences between the groups found with respect to platelets, serum albumin, serum creatinine, AST, ALT, or AFP.

***Univariate and multivariate analyses of factors associated with response***

We evaluated the relationship between response to lusutrombopag and baseline clinical characteristics using a logistic regression model (Table 2). Splenic volume identified as significant predictors in the univariate analysis. Multivariate analysis confirmed that splenic volume was an independent factor that predicts platelet response (*P* = 0.025, OR: 11.2; 95%CI: 1.354-103.0).

***Correlation between change in platelet count and splenic volume***

Splenic volume was associated with a change in platelet count (*r* = -0.524, *P* = 0.001) (Figure 3). Splenic volume increase negatively related to changes in the platelet count.

***Receiver-operating characteristic curve analysis of a response after administration of lusutrombopag***

The respective cut-off points for splenic volume were estimated using ROC curves for responders after administration of the trial drug (Figure 4). A splenic volume cut-off of 855 mL predicted responders with a sensitivity of 90% and specificity of 87.5%.

***The relationship between the response to lusutrombopag and splenic volume***

The numbers and proportions of patients with a splenic volume < 855 mL and splenic volume ≥ 855 mL were 36 (72.0%) and 14 (28.0%), respectively.

In the splenic volume < 855 mL group, the mean increase in platelet count from baseline administration of lusutrombopag was 5.68 ± 3.04 × 103/μL (*P* < 0.0001), with 97.2% (35/36) of patients as responders. In the splenic volume ≥ 855 mL group, the mean increase in platelet count from baseline was 2.03 ± 1.03 × 103/μL (*P* = 0.008), with 35.7% (5/14) of patients as responders. Unpaired *t*-test confirmed that the change in platelet count was significantly different between the groups (*P* < 0.001).

***Safety assessment***

The incidence of adverse events and adverse drug reactions was summarized in Table 3. Fever, AST increase, gastrointestinal disorders, chest pain, hypertension, and thromboembolic events were reported in 9 patients (25.7%) during treatment.

Although there were no treatment-related deaths, some serious adverse events (≥ grade 3) were reported. There were two thromboembolic events that affected portal hypertension and liver function. Portal embolic events required admission for treatment of thromboembolism.

***Risk factors for the occurrence of complications***

According to any grade AE, no significant differences between patients with and without adverse events found with respect to clinical characteristics. According to ≥ Grade 3 AE, 2 patients with portal vein thrombosis were diagnosed as having Child-Pugh class B and had a history of previous variceal bleeding with subsequent endoscopic treatment.

**DISCUSSION**

The results of this study revealed that the response to lusutrombopag was related to splenic volume in chronic liver disease. Lusutrombopag, an oral, small molecule TPO-RA, binds to the TPO receptor and acts on the transmembrane domain of human TPO receptors expressed in megakaryocytes to increase platelet production[6]. One of the reasons for thrombocytopenia is decreased levels or activity of the platelet growth factor thrombopoietin, which can lead to insufficient activation of the TPO receptor in severe chronic liver disease[2]. Therefore, TPO-RAs are particularly useful in patients with advanced chronic hepatitis or liver cirrhosis.

On the other hand, in patients with splenomegaly, the main causes of thrombocytopenia are increased splenic sequestration and destruction of platelets, whereas reduced platelet count seems to be greatly related to increased splenic size[10-14]. The present study revealed that increased splenic volume is related to negative changes in platelet count. In particular, splenic volume >855 mL was associated with insufficient increase in platelet count after the administration of appropriate doses of lusutrombopag for 7 d. We hypothesized that severe splenomegaly could reduce the efficacy seen in platelet counts due to increased splenic sequestration and destruction in spite of the TPO-RA causing sufficient platelet production. Based on the results of this phase 2b study, a dose-related increase in the maximum platelet count and duration of the maintenance of the increase in platelet count was reported[15].

When the dose of this treatment drug can be increased in case of severe splenomegaly, a treatment response may be achieved.

We recommend combination therapy with partial splenic artery embolization (PSE) and TPO-RA to increase platelet production in patients with a splenic volume >855 mL, who remain at risk of bleeding following invasive surgery. PSE is a useful method used for patients with splenomegaly and with accompanying portal hypertension. However, a large infarcted splenic volume is a risk factor for complications, including intra-abdominal abscess, portal vein thrombosis, septic shock, and post-embolization syndrome[16-17]. Previous studies reported infarcted splenic volumes between 388-540 g[18-20], and the therapeutic effect of PSE on severe splenomegaly is sometimes insufficient. Although it is enough for patients with mild splenomegaly to undergo PSE alone, thrombocytopenic patients with severe splenomegaly should be administered with lusutrombopag after an appropriate infarcted splenic volume is achieved.

We should consider that splenic volume which be influenced by sex, height, and weight. In this cohort, 90% of the non-responder group was composed of men, and body weight was significantly higher in the non-responder group compared to that in the responder group (*P* = 0.044). Previous reports have shown that splenic length and volume have independent correlations with sex, height, and weight[19]. Therefore, the influential parameters for splenic volume need to be considered in patient cohorts. Furthermore, patients enrolled in this study had a relatively large spleen size. If they had presented with mild or moderate spleen size, the results would likely have been different.

TPO-RAs are generally well tolerated, with common adverse events including AST increase, gastrointestinal disorders, and hypertension[21]. However, thromboembolic events have been reported in patients treated with TPO-RAs, the majority of whom had pre-existing cardiovascular or thromboembolic risk factors[21-22]. In particular, the administration of TPO-RAs in patients with advanced cirrhosis requires close monitoring. Severe chronic liver disease is considered as a hypercoagulable state, with increased bleeding tendency due to severe homeostatic disruption[23]. The phase-3 randomized controlled trials ENABLE-1 and ENABLE-2 studied the efficacy of TPO-RAs in patients with chronic hepatitis C and thrombocytopenia and revealed that thromboembolic complications were more frequently observed in the group treated with TPO-RAs compared to the control group[24-25]. In the present study, thromboembolic events reported in two patients (4.0%) during the observation period, requiring hospital admission. Two patients with portal vein thrombosis diagnosed as having Child-Pugh class B and had a history of previous variceal bleeding with subsequent endoscopic treatment. This suggests that patients should be carefully monitored during treatment so that potentially life-threatening thromboembolic events can be prevented or treated.

TPO-RAs can increase platelet count and decrease bleeding events. Our final objective was to minimize the administration of transfusion for reducing the incidence of bleeding events in thrombocytopenic patients. However, strategies to reduce or avoid platelet transfusions were not achieved by present the study where only the relationship between the response to lusutrombopag and splenic volume has been showed. For increasing platelet counts, we can select the optimal therapy from blood transfusion, PSE, splenectomy, and TPO-RA. The most suitable method for patients is selected by careful discussion and consideration of the benefits and disadvantages of each method. Comparative clinical trial data are needed in making correct treatment choices while maximizing efficacy and safety.

This study had some limitations. First, the study employed a retrospective design. Second, there are multiple factors which can cause thrombocytopenia in patients with chronic liver disease. These factors include anti-platelet antibodies, levels or activity of thrombopoietin, and bone marrow suppression of thrombopoiesis due to myelodysplastic syndromes and/or direct myelosuppressive effects of HCV infection.

In this study, the evaluation of influences of these factors was lacking. Therefore, further studies are warranted. Third, the number of patients was relatively small comparing the responder and non-responder groups. This could have led to a selection bias.

This study demonstrated that splenic volume influences the response to lusutrombopag in chronic liver disease. Larger spleen size appears to reduce the effect of lusutrombopag in terms of platelet count. This is the first report to assess the factors that affect the response to lusutrombopag in patients with chronic liver disease. Splenic volume should be taken into consideration when administering lusutrombopag to ensure that patients receive optimal treatment.

**ARTICLE HIGHLIGHTS**

***Research background***

Lusutrombopag is an oral, small-molecule thrombopoietin (TPO) receptor agonist (TPO-RA) used for the treatment of thrombocytopenic patients with chronic liver diseases. TPO in the peripheral blood in advanced-stage liver disease was been reduced severely. Therefore, patients with inadequate TPO production due to chronic liver disease are the principal targets of lusutrombopag.

***Research motivation***

The response to lusutrombopag is unpredictable, assuming that the drug exerts more dramatic effects in thrombocytopenia associated with severe liver disease prior to invasive surgery.

***Research objectives***

The study aimed to assess the correlation between the clinical characteristics of patients with chronic liver disease and the efficacy of lusutrombopag treatment.

***Research methods***

This multicenter retrospective study conducted at four locations in Japan. This study enrolled thrombocytopenic patients received oral lusutrombopag. We evaluated the response to lusutrombopag compared to baseline clinical characteristics in patients with chronic liver disease.

***Research results***

Splenic volume and body weight was lower in the responder group than in the non-responder group. Using a logistic regression model to assess the relationship between response to lusutrombopag and clinical characteristics, multivariate analysis confirmed that splenic volume was an independent factor that predicted the response of platelet counts (*P* = 0.025, odds ratio: 11.2; 95%CI: 1.354-103.0). Splenic volume was negatively correlated to changes in platelet count (*r* = -0.524, *P* = 0.001).

***Research conclusions***

Splenic volume influences change in platelet counts after administration of lusutrombopag in patients with chronic liver disease. Splenic volume should be taken into consideration when administering lusutrombopag to ensure that patients receive the optimal treatment. Larger spleen size appears to reduce the effect of lusutrombopag in terms of platelet count. Splenic volume should be taken into consideration when administering lusutrombopag to ensure that patients receive the optimal treatment. This is the first report to assess the factors that affect the response to lusutrombopag in patients with chronic liver disease. Splenic volume should be taken into consideration when administering lusutrombopag to ensure that patients receive optimal treatment. This multicenter retrospective study was conducted at four locations in Japan. We investigated an increase in platelet count after the trial drug administration. We evaluated the response to lusutrombopag compared to baseline clinical characteristics in patients with chronic liver disease. Splenic volume influences change in platelet counts after administration of lusutrombopag in patients with chronic liver disease. Larger spleen size appears to reduce the effect of lusutrombopag in terms of platelet count. There are multiple factors which can cause thrombocytopenia in patients with chronic liver disease. These factors include anti-platelet antibodies, levels or activity of thrombopoietin, and bone marrow suppression of thrombopoiesis due to myelodysplastic syndromes and/or direct myelosuppressive effects of HCV infection. In this study, the evaluation of influences of these factors was lacking. Therefore, further studies are warranted.

***Research perspectives***

Splenic volume should be taken into consideration when administering lusutrombopag to ensure that patients receive optimal treatment. It is not clear whether or not the combination therapy improved the long-term prognosis of these patients. Therefore, future long-term observational studies are warranted. Further studies are desired to assess multiple factors include anti-platelet antibodies, levels or activity of thrombopoietin, and bone marrow suppression of thrombopoiesis due to myelodysplastic syndromes and/or direct myelosuppressive effects of HCV infection.

**ACKNOWLEDGEMENTS**

We thank Ayumu Sugitani, of the Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital, Hokkaido, Japan, for assistance with the statistical analyses, and Robert E. Brandt, Founder, CEO, and CME, of MedEd Japan, for editing and formatting the manuscript.

**REFERENCES**

1 **Afdhal N**, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. *J Hepatol* 2008; **48**: 1000-1007 [PMID: 18433919 DOI: 10.1016/j.jhep.2008.03.009]

2 **Poordad F**. Review article: thrombocytopenia in chronic liver disease. *Aliment Pharmacol Ther* 2007; **26** Suppl 1: 5-11 [PMID: 17958514]

3 **Stiegler G**, Stohlawetz P, Peck-Radosavljevic M, Jilma B, Pidlich J, Wichlas M, Höcker P, Panzer S. Direct evidence for an increase in thrombopoiesis after liver transplantation. *Eur J Clin Invest* 1998; **28**: 755-759 [PMID: 9767375]

4 **Gangireddy VG**, Kanneganti PC, Sridhar S, Talla S, Coleman T. Management of thrombocytopenia in advanced liver disease. *Can J Gastroenterol Hepatol* 2014; **28**: 558-564 [PMID: 25222481]

5 **Peck-Radosavljevic M**. Thrombocytopenia in liver disease. *Can J Gastroenterol* 2000; **14 Suppl D**: 60D-66D [PMID: 11110614]

6 **Kim ES**. Lusutrombopag: First Global Approval. *Drugs* 2016; **76**: 155-158 [PMID: 26666417 DOI: 10.1007/s40265-015-0525-4]

7 **Katsube T**, Ishibashi T, Kano T, Wajima T. Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects. *Clin Pharmacokinet* 2016; **55**: 1423-1433 [PMID: 27209291 DOI: 10.1007/s40262-016-0411-6]

8 **Hidaka H**, Nakazawa T, Wang G, Kokubu S, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Koizumi W. Reliability and validity of splenic volume measurement by 3-D ultrasound. *Hepatol Res* 2010; **40**: 979-988 [PMID: 20887333 DOI: 10.1111/j.1872-034X.2010.00705.x]

9 **Hidaka H**. Lusutrombopag reduces the need for platelet transfusion in thrombocytopenic patients undergoing invasive procedures

10 **Eichner ER**. Splenic function: normal, too much and too little. *Am J Med* 1979; **66**: 311-320 [PMID: 371397]

11 **Dahal S**, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt VR. Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection. *Mediterr J Hematol Infect Dis* 2017; **9**: e2017019 [PMID: 28293407 DOI: 10.4084/MJHID.2017.019]

12 **Mitchell O**, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. *Hepat Med* 2016; **8**: 39-50 [PMID: 27186144 DOI: 10.2147/HMER.S74612]

13 **Djordjević J**, Svorcan P, Vrinić D, Dapcević B. [Splenomegaly and thrombocytopenia in patients with liver cirrhosis]. *Vojnosanit Pregl* 2010; **67**: 166-169 [PMID: 20337100]

14 **Patel AG**, Parker JE, Wallwork B, Kau KB, Donaldson N, Rhodes MR, O'Rourke N, Nathanson L, Fielding G. Massive splenomegaly is associated with significant morbidity after laparoscopic splenectomy. *Ann Surg* 2003; **238**: 235-240 [PMID: 12894017 DOI: 10.1097/01.sla.0000080826.97026.d8]

15 **Tateishi R**, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, Ochiai T, Fukuhara T, Kano T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. *J Gastroenterol* 2018 [PMID: 30105510 DOI: 10.1007/s00535-018-1499-2]

16 **Hayashi H**, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. *World J Gastroenterol* 2014; **20**: 2595-2605 [PMID: 24627595 DOI: 10.3748/wjg.v20.i10.2595]

17 **Witters P**, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F, Van Geet C, Cassiman D. Review article: blood platelet number and function in chronic liver disease and cirrhosis. *Aliment Pharmacol Ther* 2008; **27**: 1017-1029 [PMID: 18331464 DOI: 10.1111/j.1365-2036.2008.03674.x]

18 **Hayashi H**, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors for complications after partial splenic embolization for liver cirrhosis. *Br J Surg* 2008; **95**: 744-750 [PMID: 18412294 DOI: 10.1002/bjs.6081]

19 **Chow KU**, Luxembourg B, Seifried E, Bonig H. Spleen Size Is Significantly Influenced by Body Height and Sex: Establishment of Normal Values for Spleen Size at US with a Cohort of 1200 Healthy Individuals. *Radiology* 2016; **279**: 306-313 [PMID: 26509293 DOI: 10.1148/radiol.2015150887]

20 **Hayashi H**, Beppu T, Masuda T, Mizumoto T, Takahashi M, Ishiko T, Takamori H, Kanemitsu K, Hirota M, Baba H. Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients. *J Gastroenterol Hepatol* 2007; **22**: 1638-1642 [PMID: 17683504 DOI: 10.1111/j.1440-1746.2007.05090.x]

21 **Afdhal NH**, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. *Gastroenterology* 2014; **146**: 442-452.e1 [PMID: 24126097 DOI: 10.1053/j.gastro.2013.10.012]

22 **Grotzinger KM**, Younossi ZM, Giannini EG, Chen PJ, Rendas-Baum R, Theodore D. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. *Health Qual Life Outcomes* 2016; **14**: 49 [PMID: 27004952 DOI: 10.1186/s12955-016-0447-1]

23 **Mihăilă RG**, Cipăian RC. Eltrombopag in chronic hepatitis C. *World J Gastroenterol* 2014; **20**: 12517-12521 [PMID: 25253952 DOI: 10.3748/wjg.v20.i35.12517]

24 **Wong RSM**, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. *Blood* 2017; **130**: 2527-2536 [PMID: 29042367 DOI: 10.1182/blood-2017-04-748707]

25 **Elgebaly AS**, Ashal GE, Elfil M, Menshawy A. Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials. *Clin Appl Thromb Hemost* 2017; **23**: 928-937 [PMID: 27572890 DOI: 10.1177/1076029616663849]

**P-Reviewer:** Manenti A, Sterpetti AV, Zapater P **S-Editor:** Wang XJ

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0



**Figure 1 Axial computed tomography section (A) and 3-D reconstructed image (B) of the spleen.** Procedure of the volume measurement using virtual organ computer-aided analysis on enhanced computed tomography in an enrolled patient with splenomegaly. The total volume was 1212 mL calculated using the software.



**Figure 2 Mean changes in platelet count in all patients with splenomegaly treated with 3.0 mg/d for 7 d lusutrombopag.** Data are expressed as mean ± SD. The paired *t-*test was used to compare paired data. Max: The maximum count.



**Figure 3 Correlation between change in platelet count and splenic size in patients with cirrhosis.** Determined using Pearson’s *r* coefficient. Data are expressed as the mean ± SD.

****

**Figure 4 Receiver-operating characteristic curves for splenic size and response area under the curve.**

**Table 1 Baseline clinical characteristics**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All** | **Responder** | **Non-responder** | **P value** |
| *n* | 50 | 40 | 10 |  |
| Age (yr) | 65.9 ± 10.2 | 66.2 ± 10.2 | 64.7 ± 10.4 | 0.638 |
| Gender: Male, *n* (%) | 34 (68.0) | 25 (63.9) | 9 (90.0) | 0.138 |
| Height (m) | 1.63 ± 0.10 | 1.62 ± 0.11 | 1.64 ± 0.08 | 0.695 |
| Weight (kg) | 64.7 ± 12.1 | 63.0 ± 11.3 | 71.6 ± 13.4 | 0.044 |
| Body mass index (kg/m2) | 24.5 ± 3.92 | 24.3 ± 4.10 | 25.2 ± 3.25 | 0.548 |
| Etiology (*n*) |  |  |  | 0.717 |
| Cirrhotic/Non-cirrhotic | 48/2 | 39/1 | 9/1 |  |
| HCV/HBV/Alcohol/Non-virus | 15/6/15/12 | 13/4/11/11 | 2/2/4/1 | 0.717 |
| IPH/EHO | 1/1 | 1/0 | 0/1 |  |
| Child-Pugh | 6.94 ± 1.57 | 6.98 ± 1.62 | 6.80 ± 1.40 | 0.756 |
| MELD | 7.26 ± 3.05 | 7.02 ± 2.98 | 8.20 ± 3.33 | 0.281 |
| Liver cancer, *n* (%) | 26 (52.0) | 22 (55.2) | 4 (40.0) | 0.490 |
| Splenic volume (mL) | 741 ± 325 | 653 ± 267 | 1,092 ± 314 | <0.001 |
| Spleen vein diameter (mm) | 10.8 ± 3.60 | 10.3 ± 3.47 | 12.8 ± 3.69 | 0.059 |
| Portal diameter (mm) | 12.6 ± 3.45 | 12.3 ± 3.46 | 14.1 ± 3.12 | 0.143 |
| Procedure: RFA/IVR/Endoscopy/others (*n*) | 14/10/22/4 | 12/8/18/2 | 2/2/4/2 | 0.273 |
| APRI | 31.3 ± 17.3 | 31.7 ± 15.6 | 29.0 ± 23.8 | 0.661 |
| FIB 4 index | 12.4 ± 5.49 | 12.8 ± 5.65 | 10.9 ± 4.71 | 0.315 |
| White blood cells (/μL) | 3149 ± 1039 | 3330 ± 1051 | 2480 ± 681 | 0.020 |
| Hemoglobin (g/dL) | 12.0 ± 2.14 | 12.4 ± 1.84 | 10.7 ± 2.82 | 0.026 |
| Platelets (×104/μL) | 4.48 ± 1.07 | 4.50 ± 1.12 | 4.35 ± 0.82 | 0.778 |
| Prothrombin time (%) | 66.7 ± 12.5 | 67.1 ± 11.6 | 64.6 ± 16.3 | 0.578 |
| Total protein (g/dL) | 7.00 ± 0.70 | 7.02 ± 0.69 | 6.93 ± 0.75 | 0.726 |
| Serum albumin (g/dL) | 3.46 ± 0.54 | 3.39 ± 0.53 | 3.72 ± 0.56 | 0.089 |
| BUN (mg/dL) | 15.8 ± 5.76 | 15.5 ± 5.53 | 17.3 ± 6.69 | 0.277 |
| Serum creatinine (mg/dL) | 0.82 ± 0.21 | 0.80 ± 0.20 | 0.86 ± 0.26 | 0.443 |
| AST (IU/L) | 47.4 ± 25.6 | 48.4 ± 23.2 | 43.6 ± 35.2 | 0.602 |
| ALT (IU/L) | 36.7 ± 22.9 | 37.5 ± 21.3 | 34.2 ± 30.2 | 0.700 |
| Total bilirubin (g/dL) | 1.41 ± 0.83 | 1.40 ± 0.85 | 1.45 ± 0.76 | 0.873 |
| HbA1c (%) | 5.98 ± 1.15 | 5.97 ± 1.15 | 6.03 ± 1.23 | 0.901 |
| Ammonia (μg/dL) | 66.7 ± 42.0 | 64.3 ± 37.3 | 75.9 ± 58.5 | 0.442 |
| AFP (ng/mL)  | 33.4 ± 82.7 | 29.0 ± 80.8 | 54.2 ± 95.2 | 0.441 |
| PIVKA- II (mAU/mL) | 48.1 ± 68.4 | 51.4 ± 75.7 | 32.8 ± 26.0 | 0.493 |

Data are expressed as mean, number (%) or mean (standard derivation). IPH: Idiopathic portal hypertension; EHO: Extrahepatic portal venous obstruction; RFA: Radiofrequency ablation; IVR: Interventional radiology; MELD: Model for end-stage liver disease; APRI: AST to platelet ratio index; Fib4: Fibrosis 4 index; AFP: α-fetoprotein; PIVKA: Protein induced by vitamin K absence; BUN: Blood urea nitrogen; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; HbA1c: Glycated hemoglobin.

|  |  |  |
| --- | --- | --- |
|  | **Univariate analysis** | **Multiple analysis** |
| **Variable** |  | **OR (95%CI)** | ***P* value** | **OR (95%CI)** | ***P* value** |
| Splenic size (mL) | 1: < 723 | 13.5 (1.556-117.1) | 0.018 | 11.2 (1.354-103.0) | 0.025 |
|  | 2: ≥ 723 |  |  |  |  |
| Gender | 1: Male |  |  |  |  |
|  | 2: Female | 5.41(0.621-40.95) | 0.368 |  |  |
| Age (yr) | 1: < 69 | 1.11 (0.270-4.550) | 0.168 |  |  |
|  | 2: ≥ 69 |  |  |  |  |
| Platelets (×104/μL)  | 1: < 4.5 |  |  |  |  |
|  | 2: ≥ 4.5 | 2.02 (0.442-9.412) | 0.212 |  |  |
| Hemoglobin (g/dL) | 1: < 12.4 |  |  |  |  |
|  | 2: ≥ 12.4 | 2.581 (0.582-11.42) | 0.212 |  |  |
| BUN (mg/dL) | 1: < 15.2 | 1.66 (0.405-9.412) | 0.190 |  |  |
|  | 2: ≥ 15.2 |  |  |  |  |
| Child-Pugh | 1: < 7 | 1.56 (0.582-11.42) | 0.212 |  |  |
|  | 2: ≥ 7 |  |  |  |  |
| White blood cells (/μl) | 1: < 3000 |  |  |  |  |
|  | 2: ≥ 3000 | 4.70 (0.878-25.22) | 0.072 |  |  |
| Weight (kg) | 1: < 62 | 2.85 (0.643-12.64) | 0.168 |  |  |
|  | 2: ≥ 62 |  |  |  |  |
| Ammonia (μg/dL) | 1: < 56.5 | 1.43 (0.347-5.851) | 0.623 |  |  |
|  | 2: ≥ 56.5 |  |  |  |  |

**Table 2 Univariate and multivariate analyses of factors affecting the response for lusutrombopag**

**Table 3 Adverse events**

|  |  |  |
| --- | --- | --- |
| Fever | Any grade | 2 (4.0) |
|  | ≥ Grade 3 | 0 |
| Aspartate aminotransferase increased | Any grade | 2 (4.0) |
|  | ≥ Grade 3 | 0 |
| Gastrointestinal disorders | Any grade | 1 (2.0) |
|  | ≥ Grade 3 | 0 |
| Chest pain | Any grade | 1 (2.0) |
|  | ≥ Grade 3 | 0 |
| Hypertension | Any grade | 1 (2.0) |
|  | ≥ Grade 3 | 0 |
| Portal thrombosis | Any grade | 0 |
|  | ≥ Grade 3 | 2 (4.0) |